small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search
  • Professionals (207)
  • Capabilities (53)
  • Experience (34)
  • Insights & News (1,112)
  • Other Results (54)

Professionals 207 results

T. Reed Stephens
T. Reed Stephens
Partner
  • Washington, DC
Email
+1 202-282-5795
vCard

Partner

  • Washington, DC
Justin Levy
Justin Levy
Partner
  • New York
Email
+1 212-294-6677
vCard

Partner

  • New York
Nimalka Wickramasekera
Nimalka Wickramasekera
Partner
  • Los Angeles, 
  • Silicon Valley
Email
+1 213-615-1819
vCard

Partner

  • Los Angeles
  • Silicon Valley
View All Professionals

Capabilities 53 results

Industry

Life Sciences

Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations....Read more

Industry

Technology, Media & Telecommunications

Practice Area

Patent Litigation

Our Patent Litigation Practice is one of the country’s most active and highly regarded. Our seasoned patent litigators bring extensive courtroom experience to every matter we handle. According to Lex Machina, we are among the top three national patent defense firms in the country for number of appearances and cases filed, and we also were the top national defense firm for number of patent trials in the last five years (2018–2022)....Read more

Experience 34 results

Experience

|

April 23, 2025

Voyager Acquisition Corp. and VERAXA Biotech Announce Business Combination

Winston & Strawn represented Voyager Acquisition Corp. in its announced business combination agreement with VERAXA Biotech AG, a biopharmaceutical company developing next-generation antibody-based cancer therapies. The combination will result in VERAXA becoming a publicly traded company on Nasdaq under the ticker symbol “VERX”, with a pre-money equity valuation of $1.3 billion and up to $253 million in cash held in trust by Voyager. The transaction is expected to close in the fourth quarter of 2025, subject to regulatory and shareholder approvals....Read more

Experience

|

May 2, 2024

Winston Represented Industrial Opportunity Partners in Recapitalization of Transcendia Holdings

Winston represented its client Industrial Opportunity Partners (IOP), an Evanston, IL-based private equity firm, in a recapitalization transaction adding new capital and debt reduction for Transcendia Holdings, a Franklin Park, IL-based manufacturer and converter of custom engineered materials. The transaction will provide Transcendia with US$114M in new capital, eliminate more than $200M of the Company's debt, and further strengthen Transcendia's competitive position in the market with additional operating resources. Under the terms of the agreement, an investment fund managed by IOP and investment funds managed by Goldman Sachs Asset Management will lead the capital infusion and recapitalization, which has received unanimous support from the Company's existing second lien lenders and is further supported with a new first lien credit facility from General Atlantic Credit's Atlantic Park Fund. As a result of the transaction, IOP will assume majority ownership of Transcendia, while Goldman Sachs Asset Management, its existing equity sponsor, will maintain a significant minority stake....Read more

Experience

|

April 29, 2024

Winston advised the partners of BCF Life Sciences Group in its sale to Sparkfood

A Winston Paris team advised the partners of Diorren SAS, the holding company of BCF Life Sciences ("BCF"), in the sale of BCF Life Sciences Group to Sparkfood, SA, a subsidiary of the listed Sonae group....Read more
View All Experience

Insights & News 1,112 results

Capital Markets & Securities Law Watch

|

September 16, 2025

|

7 Min Read

The FCA’s New Prospectus Rules: A Bold Reset for UK Capital Markets

On 15 July 2025, the Financial Conduct Authority (FCA) released Policy Statement PS25/9, confirming the final rules under the Public Offers and Admission to Trading Regulations 2024 (POATRs). These reforms overhaul the UK’s prospectus regime, replacing the retained EU Prospectus Regulation and taking effect from 19 January 2026. The new framework aims to simplify capital raising, reduce costs for issuers and enhance the UK’s competitiveness as a listing venue. 

The FCA’s reforms are part of a broader government strategy to ensure regulation is targeted, proportionate and growth-oriented. They follow extensive consultation, including CP24/12 and CP25/2, and reflect recommendations from Lord Hill’s UK Listing Review and the Secondary Capital Raising Review.

Client Alert

|

September 12, 2025

|

6 Min Read

Debanking Developments: OCC Bulletins Clarify Expectations, but Key Questions Remain

In this alert, Winston’s Financial Services Industry Group examines recent developments in debanking, focusing on two new OCC bulletins that clarify regulatory expectations. While these bulletins provide new insight into how the OCC is addressing debanking under the current administration, they also leave several important questions unanswered.

The OCC’s first bulletin addresses how politicized or unlawful debanking will factor into licensing applications and Community Reinvestment Act evaluations, emphasizing the importance of fair access and treatment. The second bulletin reminds banks of their obligations under the Right to Financial Privacy Act, particularly in light of recent congressional scrutiny, and underscores the need to protect customer financial records unless disclosure is legally required.

What does this mean for you? 

Direct Sellers Update: Regulation, Law & Policy

|

September 9, 2025

|

3 Min Read

No More Click to Cancel Rule—But FTC Enforcement Actions Keep Coming

The FTC’s much-anticipated “Click to Cancel” Rule was nixed, but the FTC is not backing down. The FTC continues to use Section 5 of the FTC Act and various other regulations to bring enforcement actions against companies that fail to provide clear and conspicuous disclosures about recurring charges and easy-to-cancel options for consumers. 

View All Insights & News

Other Results 54 results

Law Glossary

What Is the DMCA?

Passed in 1998 and implemented in 2000, the Digital Millennium Copyright Act (DMCA) updated U.S. law to meet the requirements of international copyright treaties. The DMCA addresses challenging issues relating to uses of copyrighted material in the digital environment: it limits the liability of online service providers that meet certain conditions, while providing certain procedures for addressing online infringement; it prohibits circumvention of digital technologies that control or limit access to copyrighted works; and it prohibits the removal or modification of certain types of copyright management information contained in protected works. Title II of the DMCA (sometimes also referred to as the Online Copyright Infringement Liability Limitation Act, or OCILLA) is codified at Section 512, Title 17, of the United States Code....Read more

Site Content

What Is Emerging Technology?

Emerging technology is a term generally used to describe a new technology, but it may also refer to the continuing development of an existing technology; it can have slightly different meaning when used in different areas, such as media, business, science, or education. The term commonly refers to technologies that are currently developing, or that are expected to be available within the next five to ten years, and is usually reserved for technologies that are creating, or are expected to create, significant social or economic effects....Read more

Site Content

What Is Form 8-K Used For?

Form 8-K is a form required to be filed by registrants with the SEC when certain significant or “material” events occur, such as mergers and acquisitions, changes in management, and director resignations. The form generally must be filed with four business days of the event triggering disclosure....Read more
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2025. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising